Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.78 |
| ▸ | HTR2C | P28335 | 4/20 | 0.78 |
| ▸ | HTR2B | P41595 | 4/20 | 0.78 |
| ▸ | HRH2 | P25021 | 10/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4055530 | 0.92 | HTR2A (0.66) | HTR2AHTR2CHTR2BHRH2 | |
| SCHEMBL4052114 | 0.88 | HTR2A (0.78) | HTR2AHTR2CHTR2BHRH2 | |
| SCHEMBL4053933 | 0.85 | HTR2A (0.81) | HTR2AHTR2CHTR2BHRH2 | |
| SCHEMBL5349823 | 0.84 | HTR2A (0.83) | HTR2AHTR2CHTR2BHRH2 | |
| SCHEMBL5351387 | 0.83 | HRH2 (1.00) | HTR2AHTR2CHTR2BHRH2 | |
| SCHEMBL7192957 | 0.83 | HTR2A (0.79) | HTR2AHTR2CHTR2BHRH2 | |
| SCHEMBL4054716 | 0.80 | HTR2A (0.66) | HTR2AHTR2CHTR2BHRH2 | |
| SCHEMBL4052268 | 0.77 | HTR2A (0.68) | HTR2AHTR2CHTR2BHRH2 | |
| SCHEMBL6794831 | 0.77 | HRH2 (0.72) | HTR2AHTR2CHTR2BHRH2 | |
| SCHEMBL5348386 | 0.77 | HRH2 (0.77) | HTR2AHTR2CHTR2BHRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622480-B2 | Selective H1 histamine receptor antagonists; bronchial asthma, allergic rhinitis, conjunctivitis, dermatitis, urticaria and other allergic diseases; e.g. 3-(4-[1-(2-methoxyethyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]piperidin-1-ylmethyl)benzoic acid | LABORATORIOS ALMIRALL S.A. (ES) | 2009-11-24 | — | — | US | disclosed |
| US-20050176751-A1 | Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents | LABORATORIOS ALMIRALL, S.A. (ES) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176751-A1 | Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents | HRH2, HRH1, HRH4 | HTR2A 83/4885HTR2C 190/4885HTR2B 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.